Dycom Industries Inc.’s (DY - Free Report) shares jumped 8.7% on Aug 28, as the company reported solid results in second-quarter fiscal 2020 (ended Jul 27, 2019). Not only its top and bottom lines topped analysts’ expectation but also the metrics improved year over year.
During the quarter, the company reported adjusted earnings of $1.09 per share, surpassing the consensus estimate of 84 cents by 29.8%. Also, the said figure increased 3.8% on a year-over-year basis.
Dycom Industries, Inc. Price, Consensus and EPS Surprise
Revenue & Operating Highlights
Dycom’s quarterly contract revenues came in at $884.2 million, increasing 10.6% year over year. The reported figure also surpassed the consensus mark of $860.49 million by 2.8%. During the quarter, the company initiated a contract modification process that helped it generate higher revenues from a large customer program.
Organically, revenues grew 11.1% year over year (excluding storm restoration services of $3.8 million in the year-ago quarter). The upside was backed by deployment of 1-gigabit wireline networks, wireless/wireline converged networks and wireless networks. Notably, higher demand from four of its top five customers supported the growth.
The company’s top five customers contributed 78.6% to total contract revenues, increasing 12.7% organically. Dycom’s largest customer Verizon accounted for 23.2% of the total revenues. Verizon grew 39.1% y/y organically. AT&T, which contributed 20.7% to revenues, was up 13.5% organically; CenturyLink added 15.7% to total revenues and increased 29% organically; Comcast accounted for 15.1% of revenues; Windstream, representing 3.9% of the total revenues, climbed 20.7% organically. Revenues from all other customers grew 5.5% organically in the quarter.
Dycom’s backlog at the end of the reported quarter totaled $6.691 billion versus $7.051 billion at the end of fiscal first quarter. Approximately $2.639 billion of the backlog is projected to be completed in the next 12 months.
Gross margin during the quarter was 18.5%, which declined 112 basis points (bps) due to higher cost of a large customer program. Adjusted EBITDA margin also contracted 90 bps to 11.3% compared with 12.2% in the year-ago quarter.
As of Jul 27, 2019, Dycom had cash and cash equivalents of $12.6 million compared with $128.3 million on Jan 26, 2019. Long-term debt was $932.3 million at the end of the second quarter compared with $867.6 million at fiscal 2019-end.
Third-Quarter Fiscal 2020 Guidance
The company anticipates contract revenues in the range of $820-$870 million versus the Zacks Consensus Estimate of $885.69 million (considering the mid-point of the guided range). The said range indicates a decline from the year-ago figure of $848.24 million.
Adjusted earnings are anticipated within 60-80 cents per share. Considering the mid-point of this guidance, the estimated range is below the consensus mark of 88 cents per share for the quarter. Also, the said range suggests a fall from the prior-year reported figure of 98 cents per share. Dycom expects adjusted EBITDA margin to decrease from the year-ago period.
Zacks Rank & Stocks to Consider
Dycom currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same space include MasTec, Inc. (MTZ - Free Report) , North American Construction Group Ltd. (NOA - Free Report) and EMCOR Group, Inc. (EME - Free Report) . While MasTec and North American Construction sport a Zacks Rank #1 (Strong Buy), EMCOR carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
MasTec, North American Construction and EMCOR are expected to register an EPS growth rate of 32.4%, 228.6% and 15.9% this year, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>